Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Conditions: Hepatitis C Infection; HIV Infection Interventions: Drug: Glecaprevir/Pibrentasvir (G/P); Drug: Ribavirin (RBV) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Hepatitis | Hepatitis C | Infectious Diseases | Research